InVentiv Health Launches MySTRO, a Multichannel Marketing Company
--MySTRO Introduces Reptivate(TM) Virtual Detailing Solution to Accelerate the Delivery of Consistent Brand Messages to Healthcare Practitioners --PROMOTECH and PRS Franklin Rebrand as MySTRO to Reflect Expanded Expertise and Integrated Capabilities
BURLINGTON, Mass., March 8, 2012 /PRNewswire via COMTEX/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has launched MySTRO, a multichannel marketing and sales solutions company. Reflecting inVentiv's expanded expertise and integrated capabilities, MySTRO provides healthcare companies with seamless sales force support, telephone and remote personal selling, print and direct mail, sample accountability and compliance services.
MySTRO brings together two legacy inVentiv businesses: PROMOTECH and PRS Franklin. The company's new branding conveys the strength of MySTRO's integrated offerings, as well as its ability to orchestrate success by delivering innovative, comprehensive and customized marketing and sales support services to clients in the pharmaceutical, healthcare and life sciences industries. Additionally, by designing solutions based on clients' individual needs, MySTRO builds relationships with customers that allow them to remain in command of strategic business decisions.
"In an economic landscape which is demanding improved efficiency and enhanced quality, healthcare companies are under enormous pressure to reduce costs and maximize their spend related to sales and marketing activities," said Chuck Shea, Executive Vice President of inVentiv Health Commercial. "MySTRO's multichannel marketing solutions provide clients with an effective and highly efficient way to reach healthcare practitioners, support and augment field forces, fulfill orders and provide best-in-class customer service to patients. Our solutions help customers drive efficiencies, remain compliant and reduce costs. As part of inVentiv Health, MySTRO offers healthcare companies the convenience of working with a single partner that can manage all of their needs in a coordinated and collaborative way."
As part of its launch, MySTRO is also introducing Reptivate(TM), a virtual detailing product that uses cutting-edge digital technology to accelerate and enhance direct-to-healthcare provider interactions and increase prescription growth, while keeping cost levels low for clients. Reptivate's integration with MySTRO's call center CRM and sample inventory management systems presents customers with turnkey solutions for virtual detailing that include promotional offer solicitation, fulfillment and sample accountability. In addition, Reptivate - a Web-based tool - consistently delivers a brand's educational messages by allowing doctors to receive the same medical information from MySTRO's call center staff in a virtual environment as they would from sales representatives who meet with physicians in person.
"The customer experience, as a result, is better and more impactful because doctors can view rich, highly animated creative assets - using most electronic devices - without limitations or connection speed issues," Shea added. "With Reptivate, MySTRO can offer healthcare companies a complete suite of customizable services that accelerate performance."
About MySTROMySTRO, an inVentiv Health company, is a leading provider of multi-channel marketing and sales force support solutions to clients in the pharmaceutical, healthcare and life-science industries. With offices in Louisville, Colorado and Totowa and Somerset, New Jersey, and more than 50 years of experience, MySTRO brings together two legacy inVentiv businesses: PROMOTECH and PRS Franklin. It provides healthcare clients with seamless sales force support, telephone and remote personal selling, print and direct mail, warehousing, fulfillment and data management services. The company also offers complete outsourced sample accountability, regulatory and PDMA compliance services to mitigate risks and ensure the appropriate promotion and distribution of prescription and controlled-substance product samples. For more information, visit http://mystromultichannel.com/index.html .
About inVentiv HealthinVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of the acquisition anticipated by this release and any future announced acquisitions, and any additional leverage we may incur in connection with the financing thereof, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this press release are referred to documents which may be filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
SOURCE inVentiv Health, Inc.